Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
f30JvKS5UyAtsbe3
